 LOS GATOS, Calif., Aug. 2, 2021 PRNewswire -- Aridis Pharmaceuticals, Inc. Nasdaq: ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Companys common stock or common stock equivalents and warrants to purchase up to an aggregate of 2,473,778 shares of the Companys common stock, at an effective purchase price of 5.053 per share of common stock or common stock equivalent and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. 